• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高表达预示结直肠癌不良预后,且为 BRAF 突变型结直肠癌的新型治疗靶点。

High Expression Confers Poor Prognosis in Colorectal Cancer, and Represents a Novel Therapeutic Target in BRAF-Mutated Colorectal Cancer.

机构信息

Wuxi Medical College, Jiangnan University, Wuxi 214000, China.

Department of Oncology, The Affiliated Hospital of Jiangnan University, Wuxi 214000, China.

出版信息

Medicina (Kaunas). 2023 Jun 12;59(6):1133. doi: 10.3390/medicina59061133.

DOI:10.3390/medicina59061133
PMID:37374338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10301164/
Abstract

We aimed to investigate the role of expression in colorectal cancer (CRC) prognosis and evaluate its potential as a therapeutic target in -mutated CRC. : Exactly 136 samples of formalin-fixed paraffin-embedded CRC tissue specimens were obtained from patients who underwent surgical resection for CRC. The gene mutation status of the samples was detected using fluorescence PCR. expression was detected using immunohistochemistry. Survival curves with high expression and mutations were compared using the Kaplan-Meier method. A nomogram was constructed to determine the estimated overall survival probability. We also predicted the 3-year and 5-year survival rates for patients with high expression and mutations. In total, 50 samples of -mutated CRC were collected and detected expression by immunohistochemistry. The Chi-squared test was used to analyze the association between expression and -mutated CRC. : High expression and mutations are associated with poor prognosis of CRC. Multivariate survival analyses indicated that high expression and mutations are significant independent predictors of CRC prognosis. Furthermore, high expression was significantly associated with -mutated CRC, and may be a potential therapeutic target for -mutated CRC. : High expression confers poor prognosis in colorectal cancer and represents a novel therapeutic target in -mutated CRC.

摘要

我们旨在探讨在结直肠癌(CRC)中的作用,并评估其作为-突变 CRC 治疗靶点的潜力。:从接受 CRC 手术切除的患者中获得了 136 例福尔马林固定石蜡包埋的 CRC 组织标本。使用荧光 PCR 检测样本的基因突变状态。使用免疫组织化学检测 表达。使用 Kaplan-Meier 方法比较高 表达和 突变的生存曲线。构建列线图以确定估计的总生存率。我们还预测了高 表达和 突变患者的 3 年和 5 年生存率。共收集 50 例-突变 CRC 样本,并通过免疫组织化学检测 表达。使用卡方检验分析 表达与-突变 CRC 之间的关系。:高 表达和 突变与 CRC 的不良预后相关。多变量生存分析表明,高 表达和 突变是 CRC 预后的显著独立预测因子。此外,高 表达与-突变 CRC 显著相关,可能是-突变 CRC 的潜在治疗靶点。:高 表达赋予结直肠癌不良预后,代表-突变 CRC 的新型治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/45fcec1ee6e7/medicina-59-01133-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/e5ba0f6082f4/medicina-59-01133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/cad76802df0c/medicina-59-01133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/27fd899b4a3f/medicina-59-01133-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/45fcec1ee6e7/medicina-59-01133-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/e5ba0f6082f4/medicina-59-01133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/cad76802df0c/medicina-59-01133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/27fd899b4a3f/medicina-59-01133-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a33e/10301164/45fcec1ee6e7/medicina-59-01133-g004.jpg

相似文献

1
High Expression Confers Poor Prognosis in Colorectal Cancer, and Represents a Novel Therapeutic Target in BRAF-Mutated Colorectal Cancer.高表达预示结直肠癌不良预后,且为 BRAF 突变型结直肠癌的新型治疗靶点。
Medicina (Kaunas). 2023 Jun 12;59(6):1133. doi: 10.3390/medicina59061133.
2
Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.结直肠癌患者突变状态、RAS 通路信号分子表达与临床病理特征和预后的关系。
World J Gastroenterol. 2019 Feb 21;25(7):808-823. doi: 10.3748/wjg.v25.i7.808.
3
The BRAF mutation is associated with the prognosis in colorectal cancer.BRAF突变与结直肠癌的预后相关。
J Cancer Res Clin Oncol. 2014 Nov;140(11):1863-71. doi: 10.1007/s00432-014-1735-y. Epub 2014 Jun 19.
4
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.KRAS、NRAS、BRAF和PIK3CA突变对原发性结直肠癌的预后影响:一项基于人群的研究。
J Transl Med. 2016 Oct 13;14(1):292. doi: 10.1186/s12967-016-1053-z.
5
Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.伊朗东南部结直肠癌患者 KRAS 和 BRAF 的突变状态及预后价值:来自伊朗东南部的首次报告。
J Gastrointest Cancer. 2021 Jun;52(2):557-568. doi: 10.1007/s12029-020-00426-8.
6
Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.DNA错配修复缺陷与泰国散发性结直肠癌患者的良好预后相关。
World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926.
7
Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.BRAF和KRAS突变对伊朗结直肠癌患者生存的预后价值:与微卫星不稳定性相关
J Gastrointest Cancer. 2020 Mar;51(1):53-62. doi: 10.1007/s12029-019-00201-4.
8
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.BRAF V600E突变和KRAS密码子13突变预示中国结直肠癌患者的生存期较差。
BMC Cancer. 2014 Nov 3;14:802. doi: 10.1186/1471-2407-14-802.
9
Prognostic value of BRAF/MIR-17 signature and B-Raf protein expression in patients with colorectal cancer: A pilot study.结直肠癌患者 BRAF/MIR-17 标志物和 B-Raf 蛋白表达的预后价值:一项初步研究。
J Clin Lab Anal. 2021 Mar;35(3):e23679. doi: 10.1002/jcla.23679. Epub 2020 Dec 9.
10
Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.MSS 转移性结直肠癌中 BRAFV600E 和 BRCA 突变的共存:OS 延长的 mCRC 患者的患病率和病例系列。
Cancer Treat Res Commun. 2022;32:100569. doi: 10.1016/j.ctarc.2022.100569. Epub 2022 Apr 30.

引用本文的文献

1
Wnt/β-catenin signaling pathway: proteins' roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis.Wnt/β-连环蛋白信号通路:蛋白质在骨质疏松症和癌症疾病中的作用以及天然化合物对骨质疏松症的调节作用。
Mol Med. 2024 Oct 28;30(1):193. doi: 10.1186/s10020-024-00957-x.

本文引用的文献

1
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.BRAF 突变型结直肠癌模型中靶向治疗联合 VEGFR 或 WNT/β-连环蛋白信号可增强反应。
Mol Cancer Ther. 2022 Dec 2;21(12):1777-1787. doi: 10.1158/1535-7163.MCT-21-0941.
2
Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies.结直肠癌肝转移中的突变:预后意义及潜在治疗策略
Cancers (Basel). 2022 Aug 23;14(17):4067. doi: 10.3390/cancers14174067.
3
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
BRAF 突变与晚期错配修复缺陷/微卫星高度不稳定结直肠癌的不良生存结局相关。
Oncologist. 2022 Mar 11;27(3):191-197. doi: 10.1093/oncolo/oyab055.
4
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.靶向肿瘤相关成纤维细胞分泌的 WNT2 恢复树突状细胞介导的抗肿瘤免疫。
Gut. 2022 Feb;71(2):333-344. doi: 10.1136/gutjnl-2020-322924. Epub 2021 Mar 10.
5
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).使用VE1免疫组织化学对非小细胞肺癌中BRAF状态进行的真实世界评估:单实验室经验(法国尼斯LPCE)
Lung Cancer. 2020 Jul;145:58-62. doi: 10.1016/j.lungcan.2020.04.024. Epub 2020 May 5.
6
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.KRAS 或 BRAF 突变导致肝血管海绵状畸形,可通过 MAP2K-MAPK1 抑制治疗。
J Exp Med. 2020 Jul 6;217(7). doi: 10.1084/jem.20192205.
7
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer.BRAF 非小细胞肺癌中 BRAF 和 MEK 抑制剂耐药的分子机制。
Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6.
8
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.黏液分化的结直肠癌与 KRAS 或 BRAF 突变的高频发生相关,而与黏液成分的量无关。
BMC Cancer. 2020 May 8;20(1):400. doi: 10.1186/s12885-020-06913-2.
9
Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis.比较分子方法和 BRAF 免疫组织化学(VE1 克隆)检测甲状腺乳头状癌 BRAF V600E 突变:一项荟萃分析。
Head Neck Pathol. 2020 Dec;14(4):1067-1079. doi: 10.1007/s12105-020-01166-8. Epub 2020 May 1.
10
BRAF Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.BRAF 突变与甲状腺乳头状癌复发风险增加相关。
World J Surg. 2020 Aug;44(8):2685-2691. doi: 10.1007/s00268-020-05521-2.